{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:04:57Z","timestamp":1772471097339,"version":"3.50.1"},"reference-count":62,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background\/Objectives: Peritoneal mesothelioma is a rare malignancy characterized by limited therapeutic options and a poor prognosis. Genomic characterization can enhance the understanding of the molecular mechanisms that lead to this disease and can contribute to improved survival outcomes through therapeutic targets. Methods: Analysis was performed using a dataset from the AACR GENIE database (v17.0-public) comprising 204 samples from 192 patients. Data were analyzed to identify patterns in genomic alterations and clinical demographics. Within the GENIE cohort, histologic subtype information was incomplete and inconsistently reported across contributing institutions. Hence, histological subtype genomic analysis was not viable. Results: The most common somatic mutation was found in the BAP1 gene (25.98%). Other common mutations were found in the NF2 (15.19%), TP53 (9.3%) and SETD2 (8.3%) genes. Several pathways were found as potential treatment targets including the chromatin remodeling, Hippo, and p53 signaling pathways. Given the size of our dataset, we were unable to draw significant conclusions about certain demographics. Conclusions: This study presents data that can help draw conclusions on common mutations, mutual exclusivity patterns, and demographics at risk for peritoneal mesothelioma. Genomic analysis of peritoneal mesothelioma may inform possible intervention targets for therapeutic treatment.<\/jats:p>","DOI":"10.3390\/life16030385","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:06:59Z","timestamp":1772467619000},"page":"385","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inactivation of BAP1 and the Hippo Pathway Characterizes the Genomic Alterations of Peritoneal Mesothelioma"],"prefix":"10.3390","volume":"16","author":[{"given":"Maya","family":"Samuels","sequence":"first","affiliation":[{"name":"Santa Clara University, College of Arts and Sciences, Santa Clara, CA 95053, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madi","family":"Williams","sequence":"additional","affiliation":[{"name":"Santa Clara University, College of Arts and Sciences, Santa Clara, CA 95053, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0033-2654","authenticated-orcid":false,"given":"Angela","family":"Hasan","sequence":"additional","affiliation":[{"name":"Santa Clara University, College of Arts and Sciences, Santa Clara, CA 95053, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Rafie","sequence":"additional","affiliation":[{"name":"Arizona State University West, Glendale, AZ 85306, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace S.","family":"Saglimbeni","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Phoenix, AZ 85012, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6403-502X","authenticated-orcid":false,"given":"Beau","family":"Hsia","sequence":"additional","affiliation":[{"name":"School of Medicine, Creighton University, Phoenix, AZ 85012, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Nair","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sweety","family":"Aeilias","sequence":"additional","affiliation":[{"name":"CHI (Catholic Health Initiatives) Health Immanuel, CommonSpirit Health, Omaha, NE 68122, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abubakar","family":"Tauseef","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, School of Medicine, Creighton University, Omaha, NE 68178, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.21037\/tlcr.2019.12.15","article-title":"Peritoneal mesothelioma","volume":"9","author":"Greenbaum","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12199-007-0017-6","article-title":"Pathology of mesothelioma","volume":"13","author":"Inai","year":"2008","journal-title":"Environ. Health Prev. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s12199-007-0016-7","article-title":"Current therapies for malignant pleural mesothelioma","volume":"13","author":"Nakano","year":"2008","journal-title":"Environ. Health Prev. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1494111","DOI":"10.1080\/2162402X.2018.1494111","article-title":"Combination immune checkpoint blockade as an effective therapy for mesothelioma","volume":"7","author":"Fear","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_6","first-page":"659","article-title":"Malignant peritoneal mesothelioma: Clinical aspects, and therapeutic perspectives","volume":"31","author":"Boussios","year":"2018","journal-title":"Ann. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41379-020-00688-4","article-title":"Malignant peritoneal mesothelioma: Prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases","volume":"34","author":"Chapel","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_8","first-page":"1193","article-title":"Quality of life and personality traits in patients with malignant pleural mesothelioma and their first-degree caregivers","volume":"9","author":"Granieri","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.12688\/f1000research.15512.2","article-title":"Factors influencing malignant mesothelioma survival: A retrospective review of the National Mesothelioma Virtual Bank cohort","volume":"7","author":"Amin","year":"2018","journal-title":"F1000Research"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/oemed-2022-108669","article-title":"Incidence and mortality from malignant mesothelioma 1982\u20132020 and relationship with asbestos exposure: The Australian Mesothelioma Registry","volume":"80","author":"Benke","year":"2023","journal-title":"Occup Environ. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.lungcan.2005.03.004","article-title":"Epidemiology of mesothelioma\u2014A South African perspective","volume":"49","author":"Abratt","year":"2005","journal-title":"Lung Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.5271\/sjweh.1686","article-title":"Relative risk of mesothelioma associated with different levels of exposure to asbestos","volume":"17","author":"Tuomi","year":"1991","journal-title":"Scand. J. Work. Environ. Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/JS9.0000000000001900","article-title":"Assessing the global burden of mesothelioma: Trends, socioeconomic influences, and asbestos exposure\u2014A retrospective cohort study","volume":"111","author":"Zhao","year":"2025","journal-title":"Int. J. Surg."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101441","DOI":"10.1016\/j.ssmph.2023.101441","article-title":"Global, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades","volume":"23","author":"Zhu","year":"2023","journal-title":"SSM Popul. Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1183\/09031936.94.07061035","article-title":"Prognostic factors and survival in malignant pleural mesothelioma","volume":"7","author":"Damhuis","year":"1994","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s00432-024-05802-6","article-title":"Global burden of mesothelioma attributable to occupational asbestos exposure in 204 countries and territories: 1990\u20132019","volume":"150","author":"Chen","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_17","unstructured":"Syed, H.A., and Wallen, J.M. (2025). Malignant Mesothelioma. StatPearls, StatPearls Publishing."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CCO.0000000000000697","article-title":"Malignant pleural mesothelioma: Recent developments","volume":"33","author":"Sinn","year":"2021","journal-title":"Curr. Opin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMra1912719","article-title":"Perspectives on the Treatment of Malignant Pleural Mesothelioma","volume":"385","author":"Janes","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"a003566","DOI":"10.1101\/mcs.a003566","article-title":"Integrative genomic analysis of peritoneal malignant mesothelioma: Understanding a case with extraordinary chemotherapy response","volume":"5","author":"Nakken","year":"2019","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/modpathol.2016.188","article-title":"Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X","volume":"30","author":"Joseph","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101600","DOI":"10.1016\/j.esmoop.2023.101600","article-title":"Molecular alterations and potential actionable mutations in peritoneal mesothelioma: A scoping review of high-throughput sequencing studies","volume":"8","author":"Dietz","year":"2023","journal-title":"ESMO Open"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1158\/1055-9965.EPI-20-0083","article-title":"Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network","volume":"29","author":"Pass","year":"2020","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tranon.2018.01.005","article-title":"Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS","volume":"11","author":"Kim","year":"2018","journal-title":"Transl. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"29","DOI":"10.21037\/dmr-22-19","article-title":"Malignant peritoneal mesothelioma literature review: Past, present, and future","volume":"5","author":"Gregory","year":"2022","journal-title":"Dig. Med. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.21037\/tlcr.2017.05.03","article-title":"BAP1, a tumor suppressor gene driving malignant mesothelioma","volume":"6","author":"Cheung","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","article-title":"The Hippo signalling pathway and its implications in human health and diseases","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Cedres, S., Valdivia, A., Priano, I., Rocha, P., Iranzo, P., Pardo, N., Martinez-Marti, A., and Felip, E. (2025). BAP1 Mutations and Pleural Mesothelioma: Genetic Insights, Clinical Implications, and Therapeutic Perspectives. Cancers, 17.","DOI":"10.3390\/cancers17091581"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e14489","DOI":"10.1111\/cns.14489","article-title":"A TGF-\u03b2 signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response","volume":"30","author":"Duan","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"117225","DOI":"10.1016\/j.biopha.2024.117225","article-title":"A multi-omics approach to reveal critical mechanisms of activator protein 1 (AP-1)","volume":"178","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"147657","DOI":"10.1016\/j.ijbiomac.2025.147657","article-title":"The interplay between post-transcriptional RNA regulation and Wnt\/\u03b2-Catenin signaling in cancer: A Review","volume":"328","author":"Sun","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/s41416-022-01979-0","article-title":"Genomic landscape of pleural and peritoneal mesothelioma tumours","volume":"127","author":"Hiltbrunner","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ariyoshi, M., Yuge, R., Kitadai, Y., Shimizu, D., Miyamoto, R., Yamashita, K., Hiyama, Y., Takigawa, H., Urabe, Y., and Oka, S. (2024). WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations. Cancers, 16.","DOI":"10.3390\/cancers16183136"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jvh.13886","article-title":"CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes","volume":"30","author":"Ning","year":"2023","journal-title":"J. Viral Hepat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_39","first-page":"e18380","article-title":"The Rarest of the Rare: A Case of BAP1-Mutated Primary Peritoneal Mesothelioma","volume":"13","author":"Gupta","year":"2021","journal-title":"Cureus"},{"key":"ref_40","first-page":"402","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"34179","DOI":"10.1074\/jbc.M109.046755","article-title":"The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1","volume":"284","author":"Machida","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_42","unstructured":"ClinicalTrials.gov (2025, August 29). Long-Term Follow-Up of Mesothelioma Patients with Germline Mutations in BAP1 and Other Cancer-Associated Genes; NCT03830229, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03830229."},{"key":"ref_43","unstructured":"ClinicalTrials.gov (2025, August 29). Mesothelioma Stratified Therapy (MiST): A Multi-Arm Trial for Relapsed Mesothelioma Using Molecular Pre-Screening to Classify Patients into Treatment Arms Based on Their Molecular Profile; NCT03654833, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03654833."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"189267","DOI":"10.1016\/j.bbcan.2025.189267","article-title":"An overview of BAP1 biological functions and current therapeutics","volume":"1880","author":"Elsayed","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"158","DOI":"10.6004\/jadpro.2022.13.2.7","article-title":"Tazemetostat: EZH2 Inhibitor","volume":"13","author":"Straining","year":"2022","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S1470-2045(22)00277-7","article-title":"EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: A multicentre, open-label, phase 2 study","volume":"23","author":"Zauderer","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e1190","DOI":"10.1002\/ctm2.1190","article-title":"YAP\/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations","volume":"13","author":"Cunningham","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Yang, H., Hall, S.R.R., Sun, B., Zhao, L., Gao, Y., Schmid, R.A., Tan, S.T., Peng, R.W., and Yao, F. (2021). NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13071561"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"107212","DOI":"10.1016\/j.jbc.2024.107212","article-title":"The tumor suppressor NF2 modulates TEAD4 stability and activity in Hippo signaling via direct interaction","volume":"300","author":"Wu","year":"2024","journal-title":"J. Biol. Chem."},{"key":"ref_50","unstructured":"ClinicalTrials.gov (2025, August 29). A Phase I Study of IAG933 in Patients with Advanced Mesothelioma and Other Solid Tumors; NCT04857372. Updated 19 September 2025, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04857372."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","article-title":"Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers","volume":"5","author":"Chapeau","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.22.01285","article-title":"A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas","volume":"41","author":"Gounder","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3892\/ol.2021.12609","article-title":"Status of CHEK2 and p53 in patients with early-onset and conventional gastric cancer","volume":"21","author":"Machlowska","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11912-021-01098-8","article-title":"WEE1 Inhibitor: Clinical Development","volume":"23","author":"Kong","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ygyno.2023.05.063","article-title":"WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer: A biomarker-enriched phase II study","volume":"174","author":"Embaby","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_56","unstructured":"ClinicalTrials.gov (2025, August 29). Study of ASD1775 (WEE1 Inhibitor) in Combination with Paclitaxel in Advance Gastric Adenocarcinoma Patients with TP53 Mutations as Second-Line Chemotherapy; NCT02448321, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02448329."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.scib.2024.02.039","article-title":"Adavosertib-encapsulated metal-organic frameworks for p53-mutated gallbladder cancer treatment via synthetic lethality","volume":"69","author":"Li","year":"2024","journal-title":"Sci. Bull."},{"key":"ref_58","unstructured":"ClinicalTrials.gov (2025, August 29). Adavosertib (WEE1 Inhibitor) in Combination with Carboplatin and Paclitaxel in Women with Ovarian Cancer; NCT01357161, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01357161."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1158\/1078-0432.CCR-20-0219","article-title":"A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer","volume":"26","author":"Oza","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/jcp.25676","article-title":"The Emerging Role of TRAF7 in Tumor Development","volume":"232","author":"Zotti","year":"2017","journal-title":"J. Cell Physiol."},{"key":"ref_61","first-page":"E4726","article-title":"Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"105124","DOI":"10.1016\/j.jbc.2023.105124","article-title":"CARM1 arginine methyltransferase as a therapeutic target for cancer","volume":"299","author":"Santos","year":"2023","journal-title":"J. Biol. Chem."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/3\/385\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T16:23:27Z","timestamp":1772468607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/3\/385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":62,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["life16030385"],"URL":"https:\/\/doi.org\/10.3390\/life16030385","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,28]]}}}